Citizens Business Bank Trims Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Citizens Business Bank decreased its position in Eli Lilly and Company (NYSE:LLY) by 23.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,093 shares of the company’s stock after selling 335 shares during the quarter. Citizens Business Bank’s holdings in Eli Lilly and Company were worth $637,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Simon Quick Advisors LLC boosted its position in Eli Lilly and Company by 10.5% during the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after acquiring an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $363,000. Terril Brothers Inc. grew its position in shares of Eli Lilly and Company by 113.2% in the fourth quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after purchasing an additional 429 shares during the period. Hartline Investment Corp increased its stake in Eli Lilly and Company by 1.1% in the fourth quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock valued at $12,786,000 after purchasing an additional 248 shares during the last quarter. Finally, Meritage Portfolio Management lifted its position in Eli Lilly and Company by 23.4% during the fourth quarter. Meritage Portfolio Management now owns 6,377 shares of the company’s stock worth $3,717,000 after buying an additional 1,208 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on LLY. Morgan Stanley upped their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Barclays upped their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price target (up previously from $815.00) on shares of Eli Lilly and Company in a report on Tuesday. BMO Capital Markets upped their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Finally, DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a report on Wednesday, February 21st. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $731.55.

Eli Lilly and Company Stock Up 6.0 %

NYSE:LLY traded up $44.36 on Tuesday, reaching $781.56. The stock had a trading volume of 7,432,651 shares, compared to its average volume of 3,071,009. The company has a 50-day moving average of $760.89 and a 200 day moving average of $668.00. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The stock has a market cap of $742.61 billion, a P/E ratio of 134.43, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $392.26 and a 12-month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the prior year, the business posted $2.09 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 28.1% on a year-over-year basis. On average, research analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.